PB Fintech is an insurance and credit distribution platform, operating Policybazaar as the online insurance marketplace and Paisabazaar as the credit marketplace, with newer legs including PB Partners (an advisor network), PB Health (hospitals), and an international business in the UAE. In Q1 FY27, overall insurance premium reached ₹8,372 crore, up 41% year on year, with new health and term insurance growing 53% and health alone 59%. The company earns commissions and fees, and consolidated PAT margin improved from 6% a year ago to 9% in Q1 FY27, though management explicitly prioritizes growth over margin expansion. With roughly 300 platforms able to transact insurance in India, the competitive structure is crowded, but Policybazaar's brand, claims support (70,000 health claims handled in Q1 with CSAT above 90%), and scale in monthly-mode health insurance (over 30% of health business) create a leading position that is still investing for share.
The economics persist because the barriers are not in the platform itself but in demand generation and trust. The health insurance book has a fully loaded claims ratio below 80%, about 20% better than the industry, reflecting superior risk selection and underwriting alignment with insurers. ULIP persistency is 70-75% after five years versus 3-11% for mutual fund SIPs, indicating customers buy for the right reasons and stay. The renewal base is compounding: core rolling 12-month renewal revenue rose to ₹1,003 crore in Q1 FY27, up 55% year on year, and management expects renewal growth to outpace fresh business growth for the next 12 months. Switching costs are high because customers return to Policybazaar for claim assistance and porting, and the PB Care+ network of roughly 500 hospitals provides preferential treatment that deepens loyalty. PB Partners, with 1.13 lakh active advisors covering 99% of India's PIN codes, adds a distribution moat that is hard to replicate.
The inflection is the conversion of a decade of fresh policy sales into a large, sticky renewal annuity, combined with the scaling of adjacent businesses. Management guides renewals growth upwards of 50% for the next year, and the 12-month rolling renewal revenue should exceed ₹1,500 crore by mid-2027. Paisabazaar broke even on an operating basis in Q1 FY27 with a contribution margin of 41%, and the full-year FY27 EBITDA expectation is around ₹50 crore, with significant operating leverage expected as fixed costs remain stable. PB Health targets a ₹500 crore annual run rate and break-even by March 2027, with the second hospital now billing and more in the pipeline. The savings business returned to fresh growth above 20% in Q1, and GIFT City, where the company claims to be the dominant retail insurance player, is expanding dollar-denominated offerings. International expansion, funded via a planned QIP, targets the Middle East, Southeast Asia, and Europe, while the UAE business grew 31% year on year in Q1 FY27.
Management has a consistent record of under-promising and over-delivering. They guided 45% insurance premium growth and an 11% EBITDA margin for FY26 and delivered exactly those numbers. They guided new initiatives to break even by Q3 FY26, and that segment moved from -7% to -3% and then to profitability. UAE profitability, guided for Q2 FY25, has been maintained for four straight quarters. However, in Q1 FY27 they revised Paisabazaar's full-year FY27 EBITDA guidance down to roughly ₹50 crore from the earlier indicated ₹100 crore, citing continued reinvestment, and they expect PAT margin to expand toward the implied 3% of premium (currently about 2%) over the medium term. Capital allocation remains growth-oriented: they intend to raise equity via QIP for international expansion, but have maintained pro-rata rights to preserve a 26-28% stake in PB Health, and they have not diluted beyond planned needs.
The quantified earnings path is clear: with renewal revenue growing above 50% and fresh growth sustaining at 30% or more, PAT margin should climb from 9% today toward the 3%-of-premium target over the next 18-24 months, driven by operating leverage in Paisabazaar and PB Partners. The key assumption is that fresh premium growth does not fade, as management itself notes that demand trends in insurance can be short-lived after events like COVID or GST changes. The most important falsifier is regulatory action on commission caps or effort-based commissions, which could compress take rates even as volumes grow; management believes its superior book quality and efficiency would benefit from any industry-wide reduction, but the risk remains. A second watchpoint is PB Health's hospital expansion, which management acknowledges is difficult and could miss the March 2027 break-even target. The tension between softer near-term Paisabazaar EBITDA guidance and rising contribution margins resolves into a deliberate reinvestment phase, not a structural deterioration, and the renewal base provides visible compounding that should outlast any short-term growth volatility.
companyname: PB Fintech Limited ticker: POLICYBZR sector: Financial services / Insurance distribution / Fintech PB Fintech Limited runs two of India's largest financial-services marketplaces: Policybazaar for insurance and Paisabazaar for credit. The company started in 2008 as an insurance comparison website and has since evolved into a licensed composite insurance broker, a credit marketplace, a network of 500,000+ insurance agents, a corporate insurance broker, and an operator of hospitals. T...
Read the full report →capex, margin expansion, new product segment, geographic expansion
New protection premium growth guided at 30%+ driven by health and term insurance expansion
Guidance maintainedoverdeliver
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for PB Fintech Limited and 4,900+ companies.
5-day free pass. No card required.